When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day

Agile Decisions Make The Difference

While global vaccine heavyweights such as Merck & Co, Sanofi and GSK have somewhat lagged in the development of vaccines for COVID-19, smaller players have stepped up. This is especially true for highly segmented markets such as China, where agility has been important.

Different types of Covid-19 coronavirus vaccines to protect against disease or pandemic
SMALLER PLAYES SEIZE THE DAY IN COVID VACCINES DEVELOPMENT • Source: Shutterstock

Globally, a number of smaller players have shone in the development of coronavirus vaccines and that has also been the case in China, where the market is highly fragmented and hundreds of makers are vying for a share of the lucrative sector.

More from COVID-19

More from Scrip

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By 

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.